The Lymph2Cx assay is being used in real-time as a companion diagnostic in the randomized, phase III ROBUST (NCT02286062) trial testing lenalidomide/R-CHOP (R2-CHOP) versus placebo/R-CHOP in previously untreated ABC-DLBCL patients59. Here, DDIT3 is linked to diffuse large B-cell lymphoma.